Loading company…
Germantown, US-based developer of a diagnostic platform for early disease detection using signal processing and machine learning.
Headquartered in Germantown, US, OTraces develops a diagnostic platform for early disease detection that uses signal processing and machine learning, with a stated accuracy above 95% across indications such as cancer and chronic diseases. It serves researchers and diagnostic test providers on a subscription basis. Alain Cappeluti and Keith Lingenfelter founded the company, which received USD 0.08 mn in its Series D round from TCP Venture Capital on September 10, 2012. The company's valuation is listed as USD 6.424 mn. The listed stage is Series D.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in